AmBisome liposomal 50 mg prašek za koncentrat za disperzijo za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ambisome liposomal 50 mg prašek za koncentrat za disperzijo za infundiranje

gilead sciences ireland uc - amfotericin b - prašek za koncentrat za disperzijo za infundiranje - amfotericin b 50 mg / 1 viala - amfotericin b

AmBisome 50 mg prašek za koncentrat ra raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ambisome 50 mg prašek za koncentrat ra raztopino za infundiranje

gilead sciences international limited - amfotericin b - prašek za raztopino za infundiranje - amfotericin b 50 mg / 1 viala - amfotericin b

AmBisome liposomal 50 mg prašek za koncentrat za disperzijo za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ambisome liposomal 50 mg prašek za koncentrat za disperzijo za infundiranje

gilead sciences international limited - amfotericin b - prašek za koncentrat za disperzijo za infundiranje - amfotericin b 50 mg / 1 viala - amfotericin b

Dasatinib Accord Evropska unija - slovenščina - EMA (European Medicines Agency)

dasatinib accord

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastična sredstva - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Dasatinib Accordpharma Evropska unija - slovenščina - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastična sredstva - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.